ID

42780

Descripción

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00062023

Link

https://clinicaltrials.gov/show/NCT00062023

Palabras clave

Versiones (2)
  1. 4/8/16 4/8/16 -
  2. 17/9/21 17/9/21 -
Subido en

17 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Colorectal Cancer NCT00062023

Inglés

Eligibility Colorectal Cancer NCT00062023

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. male or female subjects, age 40-80 years
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
2. with >5 colorectal acf and a prior history of colorectal cancer defined as dukes a/b1 carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5 years post surgical resection (86 subjects)
Descripción

Aberrant Crypt Foci Colorectal Quantity | Colorectal Carcinoma | Dukes staging system | Colorectal Carcinoma Tumor stage | Excision Post

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1879526
UMLS CUI [1,2]
C0555952
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C0009402
UMLS CUI [3]
C1512090
UMLS CUI [4,1]
C0009402
UMLS CUI [4,2]
C1300072
UMLS CUI [5,1]
C0728940
UMLS CUI [5,2]
C0687676
3. with >5 colorectal acf and recent/current history of colorectal adenoma(s) defined as one of the following: one adenomatous polyp >1cm or two or more adenomatous polyps of any size or one adenomatous polyp of any size and a documented history of adenomatous polyp(s) (86 subjects)
Descripción

Aberrant Crypt Foci Colorectal Quantity | Adenoma of large intestine | Adenomatous Polyps Quantity size | Adenomatous Polyps History

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1879526
UMLS CUI [1,2]
C0555952
UMLS CUI [1,3]
C1265611
UMLS CUI [2]
C1302401
UMLS CUI [3,1]
C0206677
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0456389
UMLS CUI [4,1]
C0206677
UMLS CUI [4,2]
C0262926
4. no elevated risk of colorectal cancer or adenomas (20 subjects)
Descripción

Colorectal Carcinoma Risk Elevated | Adenoma of large intestine Risk Elevated

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009402
UMLS CUI [1,2]
C0035647
UMLS CUI [1,3]
C3163633
UMLS CUI [2,1]
C1302401
UMLS CUI [2,2]
C0035647
UMLS CUI [2,3]
C3163633
5. subjects will be permitted to use nasonex but all other nasal steroids are prohibited. subjects may change to nasonex but must have discontinued previous nasal steroid use for at least 30 days prior to study randomization.
Descripción

Nasonex | Steroids Nasal Prohibited

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0594492
UMLS CUI [2,1]
C0038317
UMLS CUI [2,2]
C1522019
UMLS CUI [2,3]
C0138547
6. if participant is female and of childbearing potential, she must agree to use adequate contraception and must have a negative serum pregnancy test within 14 days prior to study drug administration
Descripción

Childbearing Potential Contraceptive methods | Childbearing Potential Serum pregnancy test negative

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
UMLS CUI [2,1]
C3831118
UMLS CUI [2,2]
C0430061
7. no use of investigational agent(s) within the last 3 months or at the discretion of the medical monitor
Descripción

Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013230
8. the subject will be allowed to proceed to randomization so long as all of the following laboratory criteria are met on baseline evaluation: hgb > 10.0 g/dl, platelet count > 100,000/ul; wbc > 3,000/ul; alt < 2 x upper limit of normal; ast < 2 x upper limit of normal, and total bilirubin <1.5mg/100ml.
Descripción

Laboratory Results | Hemoglobin | Platelet Count measurement | White Blood Cell Count procedure | Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Bilirubin, total measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1254595
UMLS CUI [2]
C0019046
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0023508
UMLS CUI [5]
C0201836
UMLS CUI [6]
C0201899
UMLS CUI [7]
C0201913
9. patients requiring use of hormone modulators such as tamoxifen or arimidex will be permitted to enroll providing they meet all of the eligibility criteria noted above
Descripción

Patients Requirement Hormone Receptor Modulators | Tamoxifen | Arimidex

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C1373075
UMLS CUI [2]
C0039286
UMLS CUI [3]
C0878174
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. known diagnosis of fap, hereditary non-polyposis colon cancer (hnpcc), or inflammatory bowel disease
Descripción

Adenomatous Polyposis Coli | Hereditary Nonpolyposis Colorectal Neoplasms | Inflammatory Bowel Diseases

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032580
UMLS CUI [2]
C0009405
UMLS CUI [3]
C0021390
2. history of hypersensitivity to cox-2 inhibitors, sulfonamides, nsaids , salicylates, or ursodeoxycholic acid
Descripción

allergy to COX-2 inhibitors | Hypersensitivity Sulfonamides | Hypersensitivity Anti-Inflammatory Agents, Non-Steroidal | Hypersensitivity Salicylates | Hypersensitivity Ursodiol

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2136452
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0038760
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0003211
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0036077
UMLS CUI [5,1]
C0020517
UMLS CUI [5,2]
C0042105
3. use of nsaids, including aspirin, at any dose during the six months prior to study entry will require a three month washout period prior to eligibility beginning with the time of the last dose. participants must be off all nsaids for three months prior to study entry. individuals on cardioprotectant aspirin at any dose will not be eligible.
Descripción

Anti-Inflammatory Agents, Non-Steroidal | Aspirin | Washout Period | Aspirin Cardiotonic Agents

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0003211
UMLS CUI [2]
C0004057
UMLS CUI [3]
C1710661
UMLS CUI [4,1]
C0004057
UMLS CUI [4,2]
C0007209
4. history of gastroduodenal ulcers documented endoscopically would preclude a patient from participation in the trial
Descripción

Peptic Ulcer

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0030920
5. known inability to participate in the scheduled follow-up tests.
Descripción

Follow-up participation Unable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3274571
UMLS CUI [1,2]
C0679823
UMLS CUI [1,3]
C1299582
6. significant medical or psychiatric problems which would make the patient a poor protocol candidate, in the opinion of the principal investigator.
Descripción

Disease Protocol Compliance Limited | Mental disorders Protocol Compliance Limited

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0525058
UMLS CUI [1,3]
C0439801
UMLS CUI [2,1]
C0004936
UMLS CUI [2,2]
C0525058
UMLS CUI [2,3]
C0439801
7. "unacceptable clinical risk" to proceed (based upon the subclinical discoveries made via baseline colonoscopy and biopsies).
Descripción

Risk Clinical Unacceptable | colonoscopy | Biopsy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0035647
UMLS CUI [1,2]
C0205210
UMLS CUI [1,3]
C1883420
UMLS CUI [2]
C0009378
UMLS CUI [3]
C0005558
8. patient has undergone a total colectomy
Descripción

Total colectomy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0192871
9. patient has received chemotherapy within the past 6 months of randomization into study. topical chemotherapy will be assessed on a case-by-case basis. any history of pelvic or rectal radiation therapy will exclude a patient from participating.
Descripción

Chemotherapy | Topical Chemotherapy | Therapeutic radiology procedure Pelvis | Therapeutic radiology procedure Rectum

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C1519552
UMLS CUI [3,1]
C1522449
UMLS CUI [3,2]
C0030797
UMLS CUI [4,1]
C1522449
UMLS CUI [4,2]
C0034896
10. history of invasive carcinoma in the past five years (except patients with dukes a/b1 carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5 years post surgical resection)
Descripción

Invasive Carcinoma | Dukes staging system | Colorectal Carcinoma stage | Excision Post

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1334274
UMLS CUI [2]
C1512090
UMLS CUI [3,1]
C0009402
UMLS CUI [3,2]
C1300072
UMLS CUI [4,1]
C0728940
UMLS CUI [4,2]
C0687676
11. patients with rectal cancer are excluded except for transanal excision without radiation.
Descripción

Rectal Carcinoma | transanal excision of rectal tumor | Therapeutic radiology procedure

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007113
UMLS CUI [2]
C2066010
UMLS CUI [3]
C1522449
12. patients with acute liver disease, unexplained transaminase elevations or a history of renal stones would be excluded.
Descripción

Acute hepatopathy | Transaminases increased Etiology unknown

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3672279
UMLS CUI [2,1]
C0438717
UMLS CUI [2,2]
C0743626
13. participants will not be permitted to be randomized into the trial if any of the following laboratory values are reported at baseline : hgb < 10.0 g/dl, platelet count <100,000/ul; wbc < 3,000/ul; alt > 2 x upper limit of normal; ast > 2 x upper limit of normal, and total bilirubin >1.5mg/100ml.
Descripción

Laboratory Results | Hemoglobin | Platelet Count measurement | White Blood Cell Count procedure | Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Bilirubin, total measurement

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1254595
UMLS CUI [2]
C0019046
UMLS CUI [3]
C0032181
UMLS CUI [4]
C0023508
UMLS CUI [5]
C0201836
UMLS CUI [6]
C0201899
UMLS CUI [7]
C0201913
Volver a la parte superior de la página

Similar models

Eligibility Colorectal Cancer NCT00062023

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
1. male or female subjects, age 40-80 years
boolean
C0001779 (UMLS CUI [1])
Aberrant Crypt Foci Colorectal Quantity | Colorectal Carcinoma | Dukes staging system | Colorectal Carcinoma Tumor stage | Excision Post
Item
2. with >5 colorectal acf and a prior history of colorectal cancer defined as dukes a/b1 carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5 years post surgical resection (86 subjects)
boolean
C1879526 (UMLS CUI [1,1])
C0555952 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0009402 (UMLS CUI [2])
C1512090 (UMLS CUI [3])
C0009402 (UMLS CUI [4,1])
C1300072 (UMLS CUI [4,2])
C0728940 (UMLS CUI [5,1])
C0687676 (UMLS CUI [5,2])
Aberrant Crypt Foci Colorectal Quantity | Adenoma of large intestine | Adenomatous Polyps Quantity size | Adenomatous Polyps History
Item
3. with >5 colorectal acf and recent/current history of colorectal adenoma(s) defined as one of the following: one adenomatous polyp >1cm or two or more adenomatous polyps of any size or one adenomatous polyp of any size and a documented history of adenomatous polyp(s) (86 subjects)
boolean
C1879526 (UMLS CUI [1,1])
C0555952 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C1302401 (UMLS CUI [2])
C0206677 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0456389 (UMLS CUI [3,3])
C0206677 (UMLS CUI [4,1])
C0262926 (UMLS CUI [4,2])
Colorectal Carcinoma Risk Elevated | Adenoma of large intestine Risk Elevated
Item
4. no elevated risk of colorectal cancer or adenomas (20 subjects)
boolean
C0009402 (UMLS CUI [1,1])
C0035647 (UMLS CUI [1,2])
C3163633 (UMLS CUI [1,3])
C1302401 (UMLS CUI [2,1])
C0035647 (UMLS CUI [2,2])
C3163633 (UMLS CUI [2,3])
Nasonex | Steroids Nasal Prohibited
Item
5. subjects will be permitted to use nasonex but all other nasal steroids are prohibited. subjects may change to nasonex but must have discontinued previous nasal steroid use for at least 30 days prior to study randomization.
boolean
C0594492 (UMLS CUI [1])
C0038317 (UMLS CUI [2,1])
C1522019 (UMLS CUI [2,2])
C0138547 (UMLS CUI [2,3])
Childbearing Potential Contraceptive methods | Childbearing Potential Serum pregnancy test negative
Item
6. if participant is female and of childbearing potential, she must agree to use adequate contraception and must have a negative serum pregnancy test within 14 days prior to study drug administration
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C3831118 (UMLS CUI [2,1])
C0430061 (UMLS CUI [2,2])
Investigational New Drugs
Item
7. no use of investigational agent(s) within the last 3 months or at the discretion of the medical monitor
boolean
C0013230 (UMLS CUI [1])
Laboratory Results | Hemoglobin | Platelet Count measurement | White Blood Cell Count procedure | Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Bilirubin, total measurement
Item
8. the subject will be allowed to proceed to randomization so long as all of the following laboratory criteria are met on baseline evaluation: hgb > 10.0 g/dl, platelet count > 100,000/ul; wbc > 3,000/ul; alt < 2 x upper limit of normal; ast < 2 x upper limit of normal, and total bilirubin <1.5mg/100ml.
boolean
C1254595 (UMLS CUI [1])
C0019046 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0023508 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C0201899 (UMLS CUI [6])
C0201913 (UMLS CUI [7])
Patients Requirement Hormone Receptor Modulators | Tamoxifen | Arimidex
Item
9. patients requiring use of hormone modulators such as tamoxifen or arimidex will be permitted to enroll providing they meet all of the eligibility criteria noted above
boolean
C0030705 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C1373075 (UMLS CUI [1,3])
C0039286 (UMLS CUI [2])
C0878174 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Adenomatous Polyposis Coli | Hereditary Nonpolyposis Colorectal Neoplasms | Inflammatory Bowel Diseases
Item
1. known diagnosis of fap, hereditary non-polyposis colon cancer (hnpcc), or inflammatory bowel disease
boolean
C0032580 (UMLS CUI [1])
C0009405 (UMLS CUI [2])
C0021390 (UMLS CUI [3])
allergy to COX-2 inhibitors | Hypersensitivity Sulfonamides | Hypersensitivity Anti-Inflammatory Agents, Non-Steroidal | Hypersensitivity Salicylates | Hypersensitivity Ursodiol
Item
2. history of hypersensitivity to cox-2 inhibitors, sulfonamides, nsaids , salicylates, or ursodeoxycholic acid
boolean
C2136452 (UMLS CUI [1])
C0020517 (UMLS CUI [2,1])
C0038760 (UMLS CUI [2,2])
C0020517 (UMLS CUI [3,1])
C0003211 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0036077 (UMLS CUI [4,2])
C0020517 (UMLS CUI [5,1])
C0042105 (UMLS CUI [5,2])
Anti-Inflammatory Agents, Non-Steroidal | Aspirin | Washout Period | Aspirin Cardiotonic Agents
Item
3. use of nsaids, including aspirin, at any dose during the six months prior to study entry will require a three month washout period prior to eligibility beginning with the time of the last dose. participants must be off all nsaids for three months prior to study entry. individuals on cardioprotectant aspirin at any dose will not be eligible.
boolean
C0003211 (UMLS CUI [1])
C0004057 (UMLS CUI [2])
C1710661 (UMLS CUI [3])
C0004057 (UMLS CUI [4,1])
C0007209 (UMLS CUI [4,2])
Peptic Ulcer
Item
4. history of gastroduodenal ulcers documented endoscopically would preclude a patient from participation in the trial
boolean
C0030920 (UMLS CUI [1])
Follow-up participation Unable
Item
5. known inability to participate in the scheduled follow-up tests.
boolean
C3274571 (UMLS CUI [1,1])
C0679823 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
Disease Protocol Compliance Limited | Mental disorders Protocol Compliance Limited
Item
6. significant medical or psychiatric problems which would make the patient a poor protocol candidate, in the opinion of the principal investigator.
boolean
C0012634 (UMLS CUI [1,1])
C0525058 (UMLS CUI [1,2])
C0439801 (UMLS CUI [1,3])
C0004936 (UMLS CUI [2,1])
C0525058 (UMLS CUI [2,2])
C0439801 (UMLS CUI [2,3])
Risk Clinical Unacceptable | colonoscopy | Biopsy
Item
7. "unacceptable clinical risk" to proceed (based upon the subclinical discoveries made via baseline colonoscopy and biopsies).
boolean
C0035647 (UMLS CUI [1,1])
C0205210 (UMLS CUI [1,2])
C1883420 (UMLS CUI [1,3])
C0009378 (UMLS CUI [2])
C0005558 (UMLS CUI [3])
Total colectomy
Item
8. patient has undergone a total colectomy
boolean
C0192871 (UMLS CUI [1])
Chemotherapy | Topical Chemotherapy | Therapeutic radiology procedure Pelvis | Therapeutic radiology procedure Rectum
Item
9. patient has received chemotherapy within the past 6 months of randomization into study. topical chemotherapy will be assessed on a case-by-case basis. any history of pelvic or rectal radiation therapy will exclude a patient from participating.
boolean
C0392920 (UMLS CUI [1])
C1519552 (UMLS CUI [2])
C1522449 (UMLS CUI [3,1])
C0030797 (UMLS CUI [3,2])
C1522449 (UMLS CUI [4,1])
C0034896 (UMLS CUI [4,2])
Invasive Carcinoma | Dukes staging system | Colorectal Carcinoma stage | Excision Post
Item
10. history of invasive carcinoma in the past five years (except patients with dukes a/b1 carcinoma within 5 years of entry or any stage of colorectal cancer if at least 5 years post surgical resection)
boolean
C1334274 (UMLS CUI [1])
C1512090 (UMLS CUI [2])
C0009402 (UMLS CUI [3,1])
C1300072 (UMLS CUI [3,2])
C0728940 (UMLS CUI [4,1])
C0687676 (UMLS CUI [4,2])
Rectal Carcinoma | transanal excision of rectal tumor | Therapeutic radiology procedure
Item
11. patients with rectal cancer are excluded except for transanal excision without radiation.
boolean
C0007113 (UMLS CUI [1])
C2066010 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
Acute hepatopathy | Transaminases increased Etiology unknown
Item
12. patients with acute liver disease, unexplained transaminase elevations or a history of renal stones would be excluded.
boolean
C3672279 (UMLS CUI [1])
C0438717 (UMLS CUI [2,1])
C0743626 (UMLS CUI [2,2])
Laboratory Results | Hemoglobin | Platelet Count measurement | White Blood Cell Count procedure | Alanine aminotransferase measurement | Aspartate aminotransferase measurement | Bilirubin, total measurement
Item
13. participants will not be permitted to be randomized into the trial if any of the following laboratory values are reported at baseline : hgb < 10.0 g/dl, platelet count <100,000/ul; wbc < 3,000/ul; alt > 2 x upper limit of normal; ast > 2 x upper limit of normal, and total bilirubin >1.5mg/100ml.
boolean
C1254595 (UMLS CUI [1])
C0019046 (UMLS CUI [2])
C0032181 (UMLS CUI [3])
C0023508 (UMLS CUI [4])
C0201836 (UMLS CUI [5])
C0201899 (UMLS CUI [6])
C0201913 (UMLS CUI [7])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial